Genomic Vision (CHIX:GVP) EBIT : €-8.76 Mil (TTM As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Genomic Vision EBIT?

Genomic Vision's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was €-5.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was €-8.76 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genomic Vision's annualized ROC % for the quarter that ended in Jun. 2023 was -258.44%. Genomic Vision's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -906.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Genomic Vision's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -527.27%.

Genomic Vision EBIT Historical Data

The historical data trend for Genomic Vision's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Vision EBIT Chart

Genomic Vision Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-6.39

-4.23

-5.15

-4.89

-6.11

Genomic Vision Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT	Get a 7-Day Free Trial															-2.28	-2.61	-2.50	-3.61	-5.15

Competitive Comparison of Genomic Vision's EBIT

For the Diagnostics & Research subindustry, Genomic Vision's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genomic Vision's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomic Vision's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genomic Vision's EV-to-EBIT falls into.

Genomic Vision EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-8.76 Mil.

Genomic Vision (CHIX:GVp) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genomic Vision's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-10.578 * ( 1 - 0% )	/	( (3.925	+	4.261)	/ 2 )
=	-10.578	/	4.093
=	-258.44 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.989	-	1.425	-	( 0.76	-	max(0, 3.912	-	3.551	+	0.76	))
=	3.925

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.957	-	3.056	-	( 0.014	-	max(0, 5.702	-	2.342	+	0.014	))
=	4.261

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Genomic Vision's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-10.302	/	( ( (1.045 + max(-1.804, 0))	+	(1.228 + max(-4.583, 0)) )	/	2 )
=	-10.302	/	( ( 1.045	+	1.228 )	/	2 )
=	-10.302	/	1.1365
=	-906.47 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.237	+	1.391	+	0.169)	-	(1.425	+	0	+	2.176)
=	-1.804

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.634	+	0.29	+	-0.0019999999999998)	-	(3.056	+	0	+	2.449)
=	-4.583

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Genomic Vision's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-8.758	/	1.661
	=	-527.27 %

Genomic Vision EBIT Related Terms

Thank you for viewing the detailed overview of Genomic Vision's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomic Vision (CHIX:GVP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Vision SA (CHIX:GVp) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

80-84 rue des Meuniers, Green Square, Batiment E, Bagneux, FRA, 92220

Website

http://www.genomicvision.com

Genomic Vision SA is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics.